Mortality risk based on the presence of gout and ULT of either allopurinol (A) or benzbromarone (B).
| Gout | ULT | n | PY | CVD Mortality | All-cause Mortality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | M | MRR | HR (95% CI) | p | E | M | MRR | HR (95% CI) | p | ||||
| + | − | 286 | 1784 | 12 | 6.73 | Reference | 36 | 20.18 | Reference | ||||
| + | A* | 286 | 1825 | 1 | 0.55 | 0.08 | 0.37 (0.01–0.48) | < 0.01 | 17 | 9.32 | 0.46 | 0.39 (0.22–0.70) | < 0.01 |
| + | − | 504 | 3204 | 11 | 3.43 | Reference | 32 | 9.99 | Reference | ||||
| + | B** | 504 | 3291 | 1 | 0.30 | 0.09 | 0.07 (0.01–0.52) | 0.01 | 14 | 4.25 | 0.43 | 0.24 (0.12–0.49) | < 0.01 |
↵* HR were further adjusted for glucose level.
↵** HR were further adjusted for comorbidities of hypertension and heart disease. ULT: urate-lowering therapy; PY: person-years; CVD: cardiovascular disease; E: number of events; M: mortality rate per 1000 person-years; MRR: mortality rate ratio; A: allopurinol; B: benzbromarone.